Interestingly, the mechanism of action of the drug Nedosiran, recently approved by the U.S. Food and Drug Administration for the treatment of primary hyperoxaluria type 1, acts by directly interfering with LDHA mRNA transcription [56], providing further promising evidence for the potential of LDHA as a therapeutic target for PH. The gene discussed is LDHA; the disease is primary hyperoxaluria type 1.